Treace Medical ($TMCI) Misleading Demand and Guidance Collapse Case

• $TMCI investors filed a claim against Treace Medical for hiding competitive pressure and overstating surgeon adoption of its core bunion surgery system.

• After lowering 2024 guidance and admitting that Lapiplasty growth had slowed due to market shifts, $TMCI fell nearly 63% in one day.

• $TMCI investors can join this case to be notified about potential recovery.

Case Details:

Between May 8, 2023, and May 7, 2024, Treace Medical promoted its Lapiplasty 3D Bunion Correction System as a superior, patented surgical solution for bunion repair. The company told investors that surgeon adoption was accelerating, competitor offerings were weak, and demand remained strong. Executives repeatedly highlighted rising average selling prices and downplayed the impact of other techniques, particularly minimally invasive osteotomy systems.

But on May 7, 2024, Treace reported Q1 2024 results and slashed its full-year revenue forecast from $220–$225M to $201–$211M. On the earnings call, executives revealed that competition from new MIS osteotomy products and Lapiplasty “knockoffs” had been growing, and were now slowing the adoption of Treace’s core product. The company also admitted it was preparing to launch its own osteotomy system, contradicting prior claims that it didn’t need one.

Following the news, $TMCI fell nearly 63% on May 8, 2024.

Based on these events, $TMCI investors filed a claim against Treace Medical, accusing the company of the following:

• It misled investors about demand for Lapiplasty and failed to disclose growing competitive risks.

• It promoted inflated growth forecasts while planning a major strategic pivot behind the scenes.

Considering all the representations, investors believe Treace concealed material risks to preserve its valuation until forced to revise guidance.